The study showed that relatively few cancers harbor HRAS mutations, particularly thyroid cancer, pheochromocytoma and paraganglioma, and HNSCC, with HNSCC expressing the highest levels of HRAS transcripts. Here, HRAS is linked to paraganglioma.